Payment overview · 2025
General Payments
$1,403.91
82 reported records · 28 companies
Healthcare provider profile · identity verified
Raymond Mcallister
Allopathic & Osteopathic Physicians|Family Medicine · ERIE, PA · NPI 1255324349
Verified facts
What the public records show
CMS Open Payments records show Raymond Mcallister received $1,403.91 in general payments during 2025 across 82 reported records.
ABBVIE INC. accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Mounjaro, Ozempic, Trelegy Ellipta, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 246 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexium by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 293 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 276 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $283.41 | 20.2% | 22 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $181.33 | 12.9% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $152.82 | 10.9% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $70.31 | 5.0% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $59.55 | 4.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $57.20 | 4.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.50 | 3.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.72 | 3.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.73 | 3.3% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $43.47 | 3.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $36.78 | 2.6% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $34.93 | 2.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.92 | 2.5% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $28.05 | 2.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.22 | 1.8% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $25.15 | 1.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.97 | 1.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$23.84 | 1.7% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $22.93 | 1.6% | 1 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $20.81 | 1.5% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $19.32 | 1.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.01 | 1.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.89 | 1.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.74 | 1.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.61 | 1.1% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $15.26 | 1.1% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.94 | 1.0% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $13.50 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,403.91 | 82 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $129.24 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $104.73 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $97.61 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $93.79 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $88.82 | 7 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $87.54 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $87.54 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $87.54 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $70.31 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $59.55 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $58.68 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $57.20 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.21 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.50 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.50 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.73 | 3 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $43.47 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $36.78 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.11 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $34.93 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.92 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.60 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.60 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $28.05 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 215 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 50 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 293 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 276 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
246 | 49 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
91 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
215 | 50 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
293 | 50 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
276 | 52 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
215 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 821 | 209 |
| Atorvastatin Calcium | Atorvastatin Calcium | 643 | 197 |
| Pantoprazole Sodium | Pantoprazole Sodium | 504 | 162 |
| Celecoxib | Celecoxib | 479 | 119 |
| Lisinopril | Lisinopril | 470 | 134 |
| Gabapentin | Gabapentin | 440 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 422 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 413 | 135 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 390 | 130 |
| Metoprolol Succinate | Metoprolol Succinate | 366 | 108 |
| Meloxicam | Meloxicam | 327 | 91 |
| Losartan Potassium | Losartan Potassium | 322 | 94 |
| Omeprazole | Omeprazole | 316 | 91 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 307 | 66 |
| Mounjaro | Tirzepatide | 293 | 50 |
| Ozempic | Semaglutide | 276 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 266 | 79 |
| Duloxetine Hcl | Duloxetine Hcl | 254 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 248 | 73 |
| Synthroid | Levothyroxine Sodium | 246 | 49 |
| Trazodone Hcl | Trazodone Hcl | 245 | 64 |
| Metformin Hcl Er | Metformin Hcl | 241 | 74 |
| Prednisone | Prednisone | 239 | 144 |
| Liothyronine Sodium | Liothyronine Sodium | 228 | 58 |
| Furosemide | Furosemide | 227 | 68 |
| Metformin Hcl | Metformin Hcl | 225 | 70 |
| Eliquis | Apixaban | 215 | 50 |
| Lorazepam | Lorazepam | 203 | 59 |
| Potassium Chloride | Potassium Chloride | 195 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 189 | 57 |
| Simvastatin | Simvastatin | 187 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 56 |
| Oxycodone Hcl | Oxycodone Hcl | 176 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 174 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 51 |
| Sertraline Hcl | Sertraline Hcl | 160 | 46 |
| Famotidine | Famotidine | 157 | 53 |
| Bupropion Xl | Bupropion Hcl | 156 | 45 |
| Alprazolam | Alprazolam | 146 | 41 |
| Valacyclovir | Valacyclovir Hcl | 144 | 54 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 142 | 27 |
| Tramadol Hcl | Tramadol Hcl | 137 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 134 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 43 |
| Montelukast Sodium | Montelukast Sodium | 128 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 126 | 115 |
| Pregabalin | Pregabalin | 123 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 34 |
| Buspirone Hcl | Buspirone Hcl | 115 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 112 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 112 | 23 |
| Irbesartan | Irbesartan | 107 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 106 | 28 |
| Diazepam | Diazepam | 104 | 35 |
| Azithromycin | Azithromycin | 96 | 72 |
| Clonazepam | Clonazepam | 96 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 30 |
| Farxiga | Dapagliflozin Propanediol | 91 | 20 |
| Morphine Sulfate Er | Morphine Sulfate | 87 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 86 | 23 |
| Labetalol Hcl | Labetalol Hcl | 84 | 24 |
| Atenolol | Atenolol | 80 | 26 |
| Ezetimibe | Ezetimibe | 80 | 24 |
| Testosterone Cypionate | Testosterone Cypionate | 80 | 26 |
| Xarelto | Rivaroxaban | 80 | 19 |
| Ondansetron Odt | Ondansetron | 79 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 25 |
| Cefdinir | Cefdinir | 77 | 69 |
| Bumetanide | Bumetanide | 76 | 21 |
| Allopurinol | Allopurinol | 74 | 23 |
| Carvedilol | Carvedilol | 73 | 22 |
| Ibuprofen | Ibuprofen | 72 | 18 |
| Topiramate | Topiramate | 72 | 20 |
| Glimepiride | Glimepiride | 67 | 19 |
| Methocarbamol | Methocarbamol | 67 | 16 |
| Spironolactone | Spironolactone | 66 | 20 |
| Nifedipine Er | Nifedipine | 63 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 52 |
| Baclofen | Baclofen | 61 | 12 |
| Mirtazapine | Mirtazapine | 61 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 59 | 38 |
| Nystatin | Nystatin | 58 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 15 |
| Aripiprazole | Aripiprazole | 55 | 17 |
| Dexamethasone | Dexamethasone | 54 | 54 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 14 |
| Fluconazole | Fluconazole | 53 | 43 |
| Folic Acid | Folic Acid | 53 | 13 |
| Donepezil Hcl | Donepezil Hcl | 52 | 14 |
| Jardiance | Empagliflozin | 51 | 17 |
| Sodium Chloride | 0.9 % Sodium Chloride | 51 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | 13 |
| Linzess | Linaclotide | 50 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 49 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 48 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 46 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 44 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 14 |
| Repatha Sureclick | Evolocumab | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 14 |
| Alendronate Sodium | Alendronate Sodium | 40 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 35 |
| Temazepam | Temazepam | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Valsartan | Valsartan | 40 | 13 |
| Armour Thyroid | Thyroid,pork | 39 | suppressed |
| Mupirocin | Mupirocin | 39 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 24 |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | 11 |
| Clonidine Hcl | Clonidine Hcl | 34 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Lansoprazole | Lansoprazole | 33 | 13 |
| Sucralfate | Sucralfate | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 12 |
| Azelastine Hcl | Azelastine Hcl | 32 | suppressed |
| Epinephrine | Epinephrine | 32 | suppressed |
| Finasteride | Finasteride | 32 | 12 |
| Hydrocortisone | Hydrocortisone | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Repaglinide | Repaglinide | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 26 |
| Nitroglycerin | Nitroglycerin | 31 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 15 |
| Lithium Carbonate | Lithium Carbonate | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 28 | 20 |
| Cephalexin | Cephalexin | 27 | 26 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Progesterone | Progesterone, Micronized | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 16 |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Wegovy | Semaglutide | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 21 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 17 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 14 |
| Cefuroxime | Cefuroxime Axetil | 18 | 18 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Phenytoin | Phenytoin | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | 12 |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,403.91 · 82 records | ABBVIE INC. | ABRYSVO, ACCRUFER, Auvelity, BREZTRI, CAMZYOS, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, EVENITY, GEMTESA, INCEPTIV, Kerendia, LEQVIO, LINZESS, MOUNJARO, NEFFY, NP Thyroid 60, NURTEC ODT, NUZYRA, OTEZLA, Ohtuvayre, Omnipod, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, Rybelsus, TONMYA, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, UNITHROID, VRAYLAR, Veozah, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error